| Autor: |
J. Arzalluz-Luque, M. Millán Vázquez, R. Lamas Pérez, N. Sánchez Rodríguez, P. Gómez López, F.J. Gómez Fernández, J. Viguera Romero, C. Jurado Cobo, M. Fernández Recio, C. González Oria |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Neurology Perspectives, Vol 4, Iss 4, Pp 100168- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0496 |
| DOI: |
10.1016/j.neurop.2024.100168 |
| Popis: |
Background: Switching between calcitonin gene-related peptide (CGRP) and monoclonal antibodies (mAbs) may be a beneficial strategy after discontinuation. The aim of this study was to evaluate switching outcomes of effectiveness/tolerability. Methods: Retrospective multicentric study of migraine patients who switched to another CGRP–mAb due to lack of tolerability or effectiveness (defined as |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
